Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNBC3-Europe: FEC vs FEC-Docetaxel in Node-Negative Breast Cancer
NCT01222052Phase 3Unknown
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jan 2002
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in breast cancer, sponsored by Martin Luther University Halle-Wittenberg. Status: unknown.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01222052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222052.